Compare NXTC & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXTC | LOAN |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 51.9M |
| IPO Year | 2019 | 1999 |
| Metric | NXTC | LOAN |
|---|---|---|
| Price | $12.83 | $4.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 24.5K | 22.8K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.96% |
| EPS Growth | ★ 11.56 | 2.08 |
| EPS | N/A | ★ 0.35 |
| Revenue | ★ $22,378,000.00 | $9,688,641.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ N/A | $12.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $4.29 |
| 52 Week High | $15.74 | $6.05 |
| Indicator | NXTC | LOAN |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 33.54 |
| Support Level | $10.40 | $4.29 |
| Resistance Level | $13.47 | $4.59 |
| Average True Range (ATR) | 1.04 | 0.06 |
| MACD | 0.24 | -0.00 |
| Stochastic Oscillator | 67.19 | 16.91 |
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.